|
JPS4995971A
(enExample)
*
|
1973-01-27 |
1974-09-11 |
|
|
|
DE2448869A1
(de)
|
1973-10-19 |
1975-09-04 |
Mcneilab Inc |
4-oxo-2-imidazolidinylidenharnstoffe, verfahren zu ihrer herstellung und arzneimittel
|
|
US4025517A
(en)
*
|
1975-06-23 |
1977-05-24 |
Mcneil Laboratories, Incorporated |
4-Oxo-2-hexahydropyrimidinylidene ureas
|
|
JPS554305A
(en)
*
|
1978-06-13 |
1980-01-12 |
Nippon Zoki Pharmaceut Co Ltd |
Remedy for disease caused by stress and its preparation
|
|
US4864028A
(en)
*
|
1983-09-14 |
1989-09-05 |
Alcon Laboratories, Inc. |
Spiro-tricyclicaromatic succinimide derivatives
|
|
US5070100A
(en)
|
1983-09-14 |
1991-12-03 |
Alcon Laboratories, Inc. |
Spiro-tricyclicaromatic succinimide derivatives
|
|
GB2189699A
(en)
|
1986-04-30 |
1987-11-04 |
Haessle Ab |
Coated acid-labile medicaments
|
|
GB2189698A
(en)
|
1986-04-30 |
1987-11-04 |
Haessle Ab |
Coated omeprazole tablets
|
|
CH677886A5
(enExample)
|
1989-06-26 |
1991-07-15 |
Hans Georg Prof Dr Weder |
|
|
ATE260974T1
(de)
|
1990-06-15 |
2004-03-15 |
Scios Inc |
Transgenes, nicht-menschliches säugetier das die amyloidbildende pathologie der alzheimerschen krankheit zeigt
|
|
DE971033T1
(de)
|
1991-01-21 |
2001-05-03 |
Imperial College Of Science, Technology & Medicine |
Prüfung und Modell für Alzheimers-Krankheit
|
|
DE69233109T2
(de)
|
1992-01-07 |
2004-05-19 |
Elan Pharmaceuticals, Inc., San Francisco |
Transgene tiermodelle fur alzheimer-krankheit
|
|
US5604102A
(en)
|
1992-04-15 |
1997-02-18 |
Athena Neurosciences, Inc. |
Methods of screening for β-amyloid peptide production inhibitors
|
|
DE1001019T1
(de)
|
1993-10-27 |
2001-01-11 |
Athena Neurosciences Inc |
Transgene Tiere, die APP Allele mit der schwedischen Mutation beherbergen
|
|
US5877399A
(en)
|
1994-01-27 |
1999-03-02 |
Johns Hopkins University |
Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
|
|
ES2094688B1
(es)
|
1994-08-08 |
1997-08-01 |
Cusi Lab |
Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
|
|
FR2730932B1
(fr)
|
1995-02-27 |
1997-04-04 |
Oreal |
Nanoemulsion transparente a base de lipides amphiphiles non-ioniques fluides et utilisation en cosmetique ou en dermopharmacie
|
|
US5744346A
(en)
|
1995-06-07 |
1998-04-28 |
Athena Neurosciences, Inc. |
β-secretase
|
|
AU6383396A
(en)
|
1995-06-07 |
1996-12-30 |
Athena Neurosciences, Inc. |
Beta-secretase, antibodies to beta-secretase, and assays for detecting beta-secretase inhibition
|
|
FR2742676B1
(fr)
|
1995-12-21 |
1998-02-06 |
Oreal |
Nanoemulsion transparente a base de tensioactifs silicones et utilisation en cosmetique ou en dermopharmacie
|
|
FR2755854B1
(fr)
|
1996-11-15 |
1998-12-24 |
Oreal |
Nanoemulsion a base de lipides amphiphiles non-ioniques et cationiques et utilisations
|
|
FR2760970B1
(fr)
|
1997-03-18 |
2000-03-10 |
Oreal |
Nanoemulsions a base de lipides amphiphiles non-ioniques et de silicones aminees et utilisations
|
|
WO2000003819A1
(en)
|
1998-07-17 |
2000-01-27 |
The Penn State Research Foundation |
Full form roll finishing technique
|
|
KR100691601B1
(ko)
|
1998-09-24 |
2007-03-09 |
파마시아 앤드 업존 캄파니 엘엘씨 |
알츠하이머병 세크레타제
|
|
FR2787027B1
(fr)
|
1998-12-14 |
2001-01-12 |
Oreal |
Nanoemulsion a base d'esters gras de sucre ou d'ethers gras de sucre et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
|
|
FR2787026B1
(fr)
|
1998-12-14 |
2001-01-12 |
Oreal |
Nanoemulsion a base d'esters mixtes d'acide gras ou d'alcool gras, d'acide carboxylique et de glyceryle, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
|
|
FR2787325B1
(fr)
|
1998-12-17 |
2001-01-26 |
Oreal |
Nanoemulsion a base d'esters gras de sorbitan oxyethylenes ou non oxyethylenes, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
|
|
FR2787326B1
(fr)
|
1998-12-17 |
2001-01-26 |
Oreal |
Nanoemulsion a base d'esters gras de glycerol, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
|
|
FR2787728B1
(fr)
|
1998-12-23 |
2001-01-26 |
Oreal |
Nanoemulsion a base d'esters gras d'acide phosphorique, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
|
|
FR2787703B1
(fr)
|
1998-12-29 |
2001-01-26 |
Oreal |
Nanoemulsion a base d'ethers gras ethoxyles ou d'esters gras ethoxyles, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
|
|
FR2788007B1
(fr)
|
1999-01-05 |
2001-02-09 |
Oreal |
Nanoemulsion a base de copolymeres blocs d'oxyde d'ethylene et d'oxyde de propylene, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
|
|
FR2788449B1
(fr)
|
1999-01-14 |
2001-02-16 |
Oreal |
Nanoemulsion a base de citrates d'alkylether, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
|
|
FR2789076B1
(fr)
|
1999-02-02 |
2001-03-02 |
Synthelabo |
Derives de alpha-azacyclomethyl quinoleine, leur preparation et leur application en therapeutique
|
|
US7161962B1
(en)
|
1999-05-27 |
2007-01-09 |
Nuera Communications, Inc. |
Method and apparatus for coding modem signals for transmission over voice networks
|
|
FR2811564B1
(fr)
|
2000-07-13 |
2002-12-27 |
Oreal |
Nanoemulsion contenant des polymeres non ioniques, et ses utilisations notamment dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
|
|
AU2002241823A1
(en)
|
2001-01-11 |
2002-07-24 |
Eastman Chemical Company |
Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials
|
|
FR2819427B1
(fr)
|
2001-01-18 |
2003-04-11 |
Oreal |
Nanoemulsion translucide, son procede de fabrication et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
|
|
JP2006512401A
(ja)
|
2001-06-05 |
2006-04-13 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
ナノエマルジョンワクチン
|
|
US7476393B2
(en)
|
2002-11-29 |
2009-01-13 |
L'oreal |
Process for the preparation of a cationic nanoemulsion, and cosmetic composition
|
|
AU2004265298A1
(en)
|
2003-08-08 |
2005-02-24 |
Pharmacopeia, Inc. |
Cyclic amine BACE-1 inhibitors having a benzamide substituent
|
|
WO2005014540A1
(en)
|
2003-08-08 |
2005-02-17 |
Schering Corporation |
Cyclic amine base-1 inhibitors having a heterocyclic substituent
|
|
CA2548388A1
(en)
|
2003-12-15 |
2005-06-30 |
Schering Corporation |
Heterocyclic aspartyl protease inhibitors
|
|
US7592348B2
(en)
|
2003-12-15 |
2009-09-22 |
Schering Corporation |
Heterocyclic aspartyl protease inhibitors
|
|
US7763609B2
(en)
|
2003-12-15 |
2010-07-27 |
Schering Corporation |
Heterocyclic aspartyl protease inhibitors
|
|
US7468402B2
(en)
|
2004-03-17 |
2008-12-23 |
Baker Hughes Incorporated |
Polymeric nanoemulsion as drag reducer for multiphase flow
|
|
CA2561532A1
(en)
|
2004-04-02 |
2005-10-20 |
Merck & Co., Inc. |
Methods for detecting substances which bind to the amyloid precursor protein or beta amyloid fragments, and binding compounds
|
|
US7618978B2
(en)
|
2004-04-22 |
2009-11-17 |
Eli Lilly And Company |
Amides as BACE inhibitors
|
|
IL162288A0
(en)
|
2004-06-01 |
2005-11-20 |
Future Products Man S A |
Compositions and methods for treating neurodegenerative disorders
|
|
TW200602045A
(en)
|
2004-06-16 |
2006-01-16 |
Wyeth Corp |
Amino-5, 5-diphenylimidazolone derivatives for the inhibition of β-secretase
|
|
DE602005012825D1
(de)
|
2004-06-16 |
2009-04-02 |
Wyeth Corp |
Diphenylimidazopyrimidin- und -imidazolamine als b-sekretase-inhibitoren
|
|
AR049726A1
(es)
|
2004-07-22 |
2006-08-30 |
Schering Corp |
Amidas sustituidas inhibidoras de beta secretasa
|
|
CN101027297B
(zh)
|
2004-07-28 |
2010-09-08 |
先灵公司 |
大环β-分泌酶抑制剂
|
|
SV2006002232A
(es)
|
2004-09-21 |
2006-05-25 |
Lilly Co Eli |
Inhibidores bace ref. x-16940
|
|
GB0500683D0
(en)
|
2005-01-13 |
2005-02-23 |
Novartis Ag |
Organic compounds
|
|
AU2006205816A1
(en)
|
2005-01-13 |
2006-07-20 |
Novartis Ag |
Macrocyclic compounds useful as bace inhibitors
|
|
CN101198595A
(zh)
|
2005-06-14 |
2008-06-11 |
先灵公司 |
天冬氨酰基蛋白酶抑制剂
|
|
MX2007016175A
(es)
|
2005-06-14 |
2008-03-07 |
Schering Corp |
Inhibidor de aspartil proteasas.
|
|
SG162790A1
(en)
|
2005-06-14 |
2010-07-29 |
Schering Corp |
Aspartyl protease inhibitors
|
|
DE602006018456D1
(de)
|
2005-06-14 |
2011-01-05 |
Schering Corp |
Herstellung und verwendung von verbindungen als aspartylproteasehemmer
|
|
AR053902A1
(es)
|
2005-06-14 |
2007-05-23 |
Schering Corp |
Inhibidores de aspartil proteasa heterociclicos macrociclicos
|
|
CA2610617A1
(en)
|
2005-06-14 |
2006-12-28 |
Schering Corporation |
The preparation and use of protease inhibitors
|
|
CN101394852A
(zh)
|
2005-06-14 |
2009-03-25 |
先灵公司 |
作为蛋白酶抑制剂的化合物的制备和用途
|
|
CN101213183A
(zh)
|
2005-06-30 |
2008-07-02 |
惠氏公司 |
氨基-5-(6元)杂芳基咪唑酮化合物和在β-分泌酶调节中的用途
|
|
TW200738683A
(en)
|
2005-06-30 |
2007-10-16 |
Wyeth Corp |
Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
|
|
TW200730523A
(en)
|
2005-07-29 |
2007-08-16 |
Wyeth Corp |
Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
|
|
EP1928841A1
(en)
|
2005-09-26 |
2008-06-11 |
Wyeth a Corporation of the State of Delaware |
Amino-5- ý4- (difluoromethoxy) phenyl¨-5-phenylimidazolone compounds as inhibitors of the beta-secretase (bace)
|
|
JP2009513656A
(ja)
|
2005-10-27 |
2009-04-02 |
シェーリング コーポレイション |
複素環式アスパルチルプロテアーゼインヒビター
|
|
JP2009513670A
(ja)
|
2005-10-31 |
2009-04-02 |
シェーリング コーポレイション |
アスパルチルプロテアーゼインヒビター
|
|
JP2009520686A
(ja)
|
2005-11-21 |
2009-05-28 |
アストラゼネカ・アクチエボラーグ |
新規な２−アミノ−イミダゾール−４−オン化合物並びに認知障害、アルツハイマー病、神経変性及び認知症の治療に使用する医薬の製造におけるその使用
|
|
GB0602951D0
(en)
|
2006-02-14 |
2006-03-29 |
Novartis Ag |
Organic Compounds
|
|
US20090099217A1
(en)
|
2006-04-05 |
2009-04-16 |
Astex Therapeutics Ltd. |
2-Aminopyrimidin-4-Ones And Their Use For Treating Or Preventing Alpha Beta-Related Pathologies
|
|
GB0611064D0
(en)
|
2006-06-05 |
2006-07-12 |
Novartis Ag |
Organic compounds
|
|
PE20080155A1
(es)
|
2006-06-12 |
2008-03-10 |
Schering Corp |
Compuestos heterociclicos como inhibidores de aspartil-proteasa
|
|
TW200815449A
(en)
|
2006-06-14 |
2008-04-01 |
Astrazeneca Ab |
Novel compounds II
|
|
TW200808796A
(en)
|
2006-06-14 |
2008-02-16 |
Astrazeneca Ab |
New compounds III
|
|
TW200815443A
(en)
|
2006-06-14 |
2008-04-01 |
Astrazeneca Ab |
Novel compounds I
|
|
TW200815447A
(en)
|
2006-06-14 |
2008-04-01 |
Astrazeneca Ab |
Novel compounds IV
|
|
TW200815349A
(en)
|
2006-06-22 |
2008-04-01 |
Astrazeneca Ab |
New compounds
|
|
US20090312370A1
(en)
|
2006-07-20 |
2009-12-17 |
Kurt Laumen |
Macrocyclic compounds useful as bace inhibitors
|
|
KR20090041387A
(ko)
|
2006-07-20 |
2009-04-28 |
노파르티스 아게 |
마크로시클릭 락탐
|
|
MX2009005182A
(es)
|
2006-11-23 |
2009-05-25 |
Novartis Ag |
Derivados de 2-hidroxi-1,3-diamino-propano.
|
|
CN101668751A
(zh)
|
2006-12-12 |
2010-03-10 |
先灵公司 |
天冬氨酰蛋白酶抑制剂
|
|
CN101631779A
(zh)
|
2006-12-12 |
2010-01-20 |
先灵公司 |
含有三环系统的天冬氨酰蛋白酶抑制剂
|
|
TW200831091A
(en)
*
|
2006-12-20 |
2008-08-01 |
Astrazeneca Ab |
New compounds
|
|
CA2680307A1
(en)
|
2007-03-12 |
2008-09-18 |
Merck & Co., Inc. |
Monocyclic anilide spirolactam cgrp receptor antagonists
|
|
CL2008000784A1
(es)
|
2007-03-20 |
2008-05-30 |
Wyeth Corp |
Compuestos amino-5-[-4-(diflourometoxi) fenil sustituido]-5-fenilmidazolona, inhibidores de b-secretasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar alzheimer, deterioro cognitivo, sindrome de down, disminucion co
|
|
TW200902499A
(en)
|
2007-05-15 |
2009-01-16 |
Astrazeneca Ab |
New compounds
|
|
US20090041201A1
(en)
|
2007-08-06 |
2009-02-12 |
Carestream Health, Inc. |
Alignment apparatus for imaging system
|
|
WO2009024615A1
(en)
|
2007-08-23 |
2009-02-26 |
Novartis Ag |
Aminobenzyl-substituted cyclic sulfones useful as bace inhibitors
|
|
US20090062361A1
(en)
|
2007-08-30 |
2009-03-05 |
Allergan, Inc. |
Therapeutic hydantoins
|
|
TWI431004B
(zh)
|
2008-05-02 |
2014-03-21 |
Lilly Co Eli |
Ｂａｃｅ抑制劑
|
|
EA201100142A1
(ru)
|
2008-07-10 |
2011-10-31 |
Новартис Аг |
Циклические сулфоны, замещенные аминобензилом, применимые в качестве ингибиторов васе
|
|
WO2010047372A1
(ja)
|
2008-10-22 |
2010-04-29 |
塩野義製薬株式会社 |
Ｂａｃｅ１阻害活性を有する２－アミノピリミジン－４－オンおよび２－アミノピリジン誘導体
|
|
CA2743006C
(en)
|
2008-11-11 |
2016-02-09 |
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. |
Inclusion complexes of pinocembrin with cyclodextrin or its derivatives
|
|
AR077277A1
(es)
|
2009-07-09 |
2011-08-17 |
Lilly Co Eli |
Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
|
|
UA108363C2
(uk)
|
2009-10-08 |
2015-04-27 |
|
Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
|
|
US8563543B2
(en)
|
2009-10-08 |
2013-10-22 |
Merck Sharp & Dohme Corp. |
Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
|
|
DK2605655T3
(en)
|
2010-08-19 |
2019-02-04 |
Buck Institute For Age Res |
METHODS OF TREATING SMALL COGNITIVE DISABILITY (MCI) AND RELATED DISORDERS
|
|
US8415483B2
(en)
|
2010-12-22 |
2013-04-09 |
Astrazeneca Ab |
Compounds and their use as BACE inhibitors
|
|
US20120165346A1
(en)
|
2010-12-22 |
2012-06-28 |
Astrazeneca Ab |
Compounds and their use as BACE inhibitors
|
|
US8877744B2
(en)
|
2011-04-04 |
2014-11-04 |
Hoffmann-La Roche Inc. |
1,4-Oxazepines as BACE1 and/or BACE2 inhibitors
|
|
ES2769578T3
(es)
|
2013-02-12 |
2020-06-26 |
Buck Inst Res Aging |
Hidantoínas que modulan el procesamiento de APP mediado por BACE
|
|
CN108349905A
(zh)
*
|
2015-08-27 |
2018-07-31 |
南顿欧洲有限责任公司 |
用于app选择性bace抑制的组合物及其用途
|